News
ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine Kinases (c-Abl kinases), announces that the final results ...
INmune Bio Inc. (NASDAQ: INMB) (“INmune” or “the Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to ...
Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of September 2025, which is payable ...
Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025 Venous malformations are the most common ...
Oral semaglutide (Rybelsus ®) is now the first and only oral GLP-1 RA approved for type 2 diabetes, with proven cardiovascular benefits 1; This approval is based on results from ...
Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer
(Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M.
Her appointment follows Atavistik Bio’s recent initiation of a Phase 1 clinical trial evaluating ATV-1601, an allosteric selective inhibitor for AKT1 E17K-driven solid tumors She will also play a ...
(p=0.0919). Clinical improvement in King’s Sarcoidosis Questionnaire (KSQ)-Lung score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0479). Greater proportion of ...
Microbot Medical Inc. (Nasdaq: MBOT) (“Microbot” or the “Company”), today announced the entry into definitive agreements for the exercise of certain outstanding preferred investment options to ...
The DoD award will support a three-year study of intranasal anti-CD3 in the acute phase of SCI, aimed at patients who present to the hospital immediately following injury. Complementing this, a ...
Revised label allows treatment of DEB patients from birth. VYJUVEK can now be applied by patients and caregivers . PITTSBURGH, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, ...
The poster presentation can be found on Alterity’s website here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback